Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 403,074
  • Shares Outstanding, K 29,019
  • Annual Sales, $ 65,320 K
  • Annual Income, $ -81,890 K
  • EBIT $ -73 M
  • EBITDA $ -68 M
  • 60-Month Beta 0.95
  • Price/Sales 6.01
  • Price/Cash Flow N/A
  • Price/Book 3.15

Options Overview Details

View History
  • Implied Volatility 147.17% (-3.24%)
  • Historical Volatility 53.15%
  • IV Percentile 65%
  • IV Rank 41.11%
  • IV High 273.66% on 03/17/25
  • IV Low 58.87% on 06/09/25
  • Expected Move (DTE 10) 1.96 (14.07%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 7
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 1,250
  • Open Int (30-Day) 1,318
  • Expected Range 11.94 to 15.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -0.55
  • Prior Year -1.06
  • Growth Rate Est. (year over year) +56.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.02 +6.68%
on 02/20/26
15.68 -11.42%
on 03/04/26
+0.06 (+0.43%)
since 02/09/26
3-Month
12.09 +14.89%
on 01/20/26
17.15 -19.01%
on 12/29/25
-0.75 (-5.12%)
since 12/09/25
52-Week
4.09 +239.61%
on 04/09/25
17.15 -19.01%
on 12/29/25
+6.67 (+92.38%)
since 03/07/25

Most Recent Stories

More News
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV)...

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

Continuing Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA) Following Positive Phase 2b RSVHR Results for Zelicapavir, an N-Protein Inhibitor in Development...

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological...

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic...

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced...

ENTA : 13.89 (+2.58%)
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Zelicapavir Results in Shortened Symptom Duration in Pediatric Patients EDP-323 is Highly Effective in a Post-Exposure Prophylaxis Setting

ENTA : 13.89 (+2.58%)

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

3rd Resistance Point 15.03
2nd Resistance Point 14.53
1st Resistance Point 14.21
Last Price 13.89
1st Support Level 13.39
2nd Support Level 12.89
3rd Support Level 12.57

See More

52-Week High 17.15
Last Price 13.89
Fibonacci 61.8% 12.16
Fibonacci 50% 10.62
Fibonacci 38.2% 9.08
52-Week Low 4.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar